Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541552 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL6492774 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL5698951 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186548 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL15154705 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL2599515 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186572 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL20262054 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186565 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186569 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | LUC THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | LUC THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9540324-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | LUC THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540324-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | LUC THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-1069022-A | 4-[2-(2-hydroxyl-2-benzene ethylamino) oxyethyl group that is used for the treatment of obesity and correlation behavior] phenylacetic acid derivatives | ICI PLC (GB) | 1993-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | HTR1A 200/4885HTR2B 130/4885CHRM2 836/4885 |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | HTR1A 278/4885HTR2B 322/4885CHRM2 123/4885 |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | HTR1A 200/4885HTR2B 130/4885CHRM2 836/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | HTR1A 200/4885HTR2B 130/4885CHRM2 836/4885 |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | HTR1A 200/4885HTR2B 130/4885CHRM2 836/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | HTR1A 2671/4885HTR2B 2102/4885CHRM2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.